Skip to main content
Premium Trial:

Request an Annual Quote

Consortium Created to Identify Kinases for Drug Discovery

NEW YORK (GenomeWeb News) – A consortium comprising six industry players and academic partners has been created to identify kinases that could serve as drug targets.

The consortium consists of drug discovery firm SARomics Biostructures; medicinal chemistry company Prestwick Chemical; contract service organization ProQinase; the University of Turin in Italy; the Israel Structural Proteomics Center at the Weizmann Institute of Science; and the TechMedIll platform of the University of Strasbourg, France.

The EU 7th Framework Program "Research for the Benefit of SMEs" is providing €1.1 million ($1.4 million) to the consortium called the Translational Kinase Tumor Inhibitor Discovery Consortium, or TAKTIC.

"The merging of the highly complementary capabilities of the six partners within the TAKTIC Consortium enables an efficient and versatile kinase drug discovery platform that will target some challenging and medically important kinases," TAKTIC said in a statement.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.